Back to Journals » OncoTargets and Therapy » Volume 12

A case of small-cell lung cancer with adrenocorticotropic hormone deficiency induced by nivolumab

Authors Zhu Y, Wu HH, Wang W

Received 10 November 2018

Accepted for publication 21 January 2019

Published 25 March 2019 Volume 2019:12 Pages 2181—2186

DOI https://doi.org/10.2147/OTT.S194094

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Dr Arseniy Yuzhalin


Yan Zhu,1 Hong Hua Wu,2 Wei Wang2

1Department of Oncology, Peking University First Hospital, Beijing, China; 2Department of Endocrinology, Peking University First Hospital, Beijing, China

Abstract: Anti-programmed death-1 (anti-PD-1) monoclonal antibodies, such as nivolumab, have been used for the treatment of various types of cancers, and excellent efficacy has been shown in some patients. The adverse effects of anti-PD-1 antibodies relating to autoimmunity are different from traditional chemotherapeutic drugs and may involve many organs including the endocrine system. We herein describe a case of adrenocorticotropic hormone deficiency during the treatment of advanced small-cell lung cancer, probably caused by nivolumab-induced hypophysitis. The case showed nonspecific, insidious, as well as potentially life-threatening characters of immune-related adverse effects. It is important for physicians to acknowledge clinical features of the rare side effect and take appropriate and prompt treatment.

Keywords: PD-1 inhibitor, ACTH deficiency, immune checkpoint inhibitor, hypophysitis, immune-related adverse events

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]